<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20131202144600Z</creation_date><modification_date>D:20150127104600Z</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-273_h_dec_7.pdf</pdf_file></head><body><section><header>en en</header><p>european commission
 bruxelles, 26.2.2015c(2015)1427 (final)</p></section><section><header>commission implementing decisionof 26.2.2015
 amending the marketing authorisation granted by decision c(2004)1765 for &quot;lysodren - 
 mitotane&quot;, a medicinal product for human use following an assessment of a periodic safety 
 update report under article 28 of regulation (ec) no 726/2004</header><p>(text with eea relevance) (only the french text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decisionof 26.2.2015
 amending the marketing authorisation granted by decision c(2004)1765 for &quot;lysodren - 
 mitotane&quot;, a medicinal product for human use following an assessment of a periodic safety 
 update report under article 28 of regulation (ec) no 726/2004</header><p>(text with eea relevance)(only the french text is authentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 726/2004 of the european parliament and of the council of 
 31 march 2004 laying down community procedures for the authorisation and supervision of 
 medicinal products for human and veterinary use and establishing a european medicines agency
 1, and in particular article 10 and 28 thereof,having regard to the opinion of the european medicines agency, formulated on 18 december 
 2014 by the committee for medicinal products for human use on the periodic safety update 
 report for this medicinal product,
 whereas:
 (1)
 the placing on the market of the medicinal product &quot;lysodren - mitotane&quot; was authorised 
 by commission decision c(2004)1765 of 28 april 2004.
 (2)
 the marketing authorisation holder submitted a periodic safety update report for this 
 medicinal product. this report was assessed by the pharmacovigilance risk assessment 
 committee as to whether the marketing authorisation(s) concerned should be maintained, 
 varied, suspended or withdrawn.
 (3)
 the scientific assessment performed by the committee for medicinal products for human 
 use, the conclusions of which are set out in annex iv to this decision, shows that a 
 decision should be taken amending the marketing authorisation for the medicinal product 
 concerned.
 (4)
 decision c(2004)1765 should therefore be amended accordingly. the community 
 register of medicinal products should also be updated.
 1oj l 136, 30.4.2004, p. 1.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>(5)for the sake of clarity and transparency, it is appropriate, following the amendment of 
 part or parts of the annexes, to provide for a consolidated version thereof. the annexes 
 to decision c(2004)1765 should therefore be replaced.
 (6)
 the measures provided for in this decision are in accordance with the opinion of the 
 standing committee on medicinal products for human use,
 has adopted this decision:
 article 1decision c(2004)1765 is amended as follows:1) annex i is replaced by the text set out in annex i to this decision;
 2) annex ii is replaced by the text set out in annex ii to this decision;
 3) annex iii is replaced by the text set out in annex iii to this decision.
 article 2this decision is addressed to laboratoire hra pharma, 15 rue b√©ranger, f-75003 paris, france.done at brussels, 26.2.2015
 for the commissionladislav miko
 acting director-general</p></section></body></xml>